Last reviewed · How we verify

Fluoxetine + outpatient cognitive behavioral therapy

National Institute on Drug Abuse (NIDA) · FDA-approved active Small molecule

Fluoxetine increases serotonin availability in the brain while cognitive behavioral therapy teaches patients to identify and modify maladaptive thought patterns and behaviors.

Fluoxetine increases serotonin availability in the brain while cognitive behavioral therapy teaches patients to identify and modify maladaptive thought patterns and behaviors. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.

At a glance

Generic nameFluoxetine + outpatient cognitive behavioral therapy
Also known asProzac
SponsorNational Institute on Drug Abuse (NIDA)
Drug classSSRI + psychotherapy combination
TargetSerotonin transporter (SERT)
ModalitySmall molecule
Therapeutic areaPsychiatry / Mental Health
PhaseFDA-approved

Mechanism of action

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake of serotonin at the synaptic cleft, increasing serotonin concentration and improving mood regulation. Cognitive behavioral therapy (CBT) is a structured psychotherapeutic intervention that helps patients recognize negative thought patterns and develop coping strategies. The combination leverages both pharmacological and behavioral approaches to treat psychiatric conditions more effectively than either modality alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: